These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1222 related articles for article (PubMed ID: 33987427)

  • 1. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
    Tacke F; Weiskirchen R
    Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the recent advances in antifibrotic therapy.
    Tacke F; Weiskirchen R
    Expert Rev Gastroenterol Hepatol; 2018 Nov; 12(11):1143-1152. PubMed ID: 30261763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?].
    Huber Y; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):68-73. PubMed ID: 31931543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the cellular interactome of non-alcoholic fatty liver disease.
    Wallace SJ; Tacke F; Schwabe RF; Henderson NC
    JHEP Rep; 2022 Aug; 4(8):100524. PubMed ID: 35845296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.
    Connolly JJ; Ooka K; Lim JK
    J Clin Transl Hepatol; 2018 Sep; 6(3):264-275. PubMed ID: 30271738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future pharmacological therapies for NAFLD/NASH.
    Sumida Y; Yoneda M
    J Gastroenterol; 2018 Mar; 53(3):362-376. PubMed ID: 29247356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
    Tacke F
    Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment Options in Non-alcoholic Fatty Liver Disease].
    Kim W
    Korean J Gastroenterol; 2017 Jun; 69(6):353-358. PubMed ID: 28637104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    Tacke F; Puengel T; Loomba R; Friedman SL
    J Hepatol; 2023 Aug; 79(2):552-566. PubMed ID: 37061196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage.
    Segal-Salto M; Barashi N; Katav A; Edelshtein V; Aharon A; Hashmueli S; George J; Maor Y; Pinzani M; Haberman D; Hall A; Friedman S; Mor A
    JHEP Rep; 2020 Feb; 2(1):100064. PubMed ID: 32039405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease.
    Jiao J; Sanchez JI; Saldarriaga OA; Solis LM; Tweardy DJ; Maru DM; Stevenson HL; Beretta L
    JHEP Rep; 2023 Feb; 5(2):100628. PubMed ID: 36687470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets.
    Higuera-de la Tijera F; Servín-Caamaño AI
    World J Hepatol; 2015 Jun; 7(10):1297-301. PubMed ID: 26052375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis.
    Barreyro FJ; Holod S; Finocchietto PV; Camino AM; Aquino JB; Avagnina A; Carreras MC; Poderoso JJ; Gores GJ
    Liver Int; 2015 Mar; 35(3):953-66. PubMed ID: 24750664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
    Polyzos SA; Kang ES; Boutari C; Rhee EJ; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154203. PubMed ID: 32151660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current treatment of non-alcoholic fatty liver disease.
    Paternostro R; Trauner M
    J Intern Med; 2022 Aug; 292(2):190-204. PubMed ID: 35796150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.